SISAQOL-IMI provides guidance for implementing patient-reported outcomes in cancer clinical trials The SISAQOL-IMI consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), just announced the publication of its pivotal paper in The Lancet Oncology outlining how its recommendations for patient-reported outcomes (PROs) in cancer clinical trials were developed.
https://www.news-medical.net/n....ews/20251126/SISAQOL